Rezolute is a clinical stage biotechnology company developing targeted therapies for metabolic diseases. Co.'s key clinical program, RZ358, is an antibody therapy as a potential treatment for congenital hyperinsulinism, a rare pediatric genetic disorder. RZ358 is an intravenously administered human monoclonal antibody that binds to a site on the insulin receptor found across effector cells throughout the body in the liver, fat, and muscle. Co. is developing RZ402, a small molecule plasma kallikrein inhibitor for use in diabetic macular edema (DME). RZ402 is designed to improve compliance and treatment outcomes for patients with DME. The RZLT stock yearly return is shown above.
The yearly return on the RZLT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RZLT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|